A Study Of PF-05175157 In Healthy Volunteers

• Drug: PF-05175157 or Placebo
  One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
• Drug: PF-05175157 or Placebo
  One dose of PF-05175157 will be administered as a powder-in-capsule immediately after breakfast; correspondingly, one dose of a matched powder-in-capsule placebo will be administered immediately after breakfast.

• Experimental: 10 mg PF-05175157 or Placebo
  Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
  Intervention: Drug: PF-05175157 or Placebo
• Experimental: 30 mg PF-05175157 or Placebo
  Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
  Intervention: Drug: PF-05175157 or Placebo
• Experimental: 100 mg PF-05175157 or Placebo
  Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
  Intervention: Drug: PF-05175157 or Placebo
• Experimental: 300 mg PF-05175157 or Placebo
  Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
  Intervention: Drug: PF-05175157 or Placebo
• Experimental: 600 mg PF-05175157 or Placebo
  Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
  Intervention: Drug: PF-05175157 or Placebo
• Experimental: 800 mg PF-05175157 or Placebo
  Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
  Intervention: Drug: PF-05175157 or Placebo
• Experimental: xxx mg PF-05175157 or Placebo
  Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
  Intervention: Drug: PF-05175157 or Placebo

Inclusion Criteria:

• Healthy male and/or female (non child-bearing potential) subjects between the ages of 18 and 45 years (inclusive).
• Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurements, 12-lead ECG and clinical laboratory tests.
• In addition, subjects must have normal chest x-ray, normal pulmonary function tests and normal ophthalmological examination.
• Body Mass Index (BMI) of 17.5 to 29.5 kg/m2; and a total body weight > 50 kg (110 lbs).

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies).
• Evidence or history of any chronic ongoing or current pulmonary disease.
• History of smoking in the past 5 years or history or evidence of habitual use of other (non-smoked) tobacco or nicotine-containing products within 3 months of Screening or positive cotinine test at Screening or Day 0.
• Active ocular disease including infection, glaucoma, seasonal allergies, dry-eye symptoms or retinal/optic nerve disease.
• Evidence or history of 'dry eye-syndrome', Meibomian gland disease, ocular inflammation (eg, uveitis, iritis), chronic blepharitis, any eye surgery including Lasik, any mechanical injury or chemical exposure to the ocular surface, use of ocular lubricants, or use of contact lenses.